Regulating glucagon secretion: somatostatin in the spotlight
Summary of timing variables to experiment with Here is a quick reference table for the variables you can adjust: What the clinical trial data tells us about timing The phase 2 retatrutide trial published in the New England Journal of Medicine enrolled 338 participants and tested doses ranging from 1 mg to 12 mg over 48 weeks
Obtain an eGFR at least annually in all patients taking JANUMET
A randomized, double-blind, placebo-controlled trial found that mulberry extract decreased total glucose and insulin rises without significant side effects
Clinical Results and Safety Phase 2 clinical trials have reported encouraging weight loss outcomes, with participants receiving the highest doses achieving an average body weight reduction of approximately 24% over 48 weeks
as a peptide, it is highly sensitive to temperature, light, and contamination, making correct storage essential for safety and integrity